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Other names: GTBP; HSAP; HNPCC5 
Location: 2p16 
Local order: Genes flanking MSH6 in centromere to 
telomere direction on 2p16 are:  
HTLF (2p22-p16) (human T-cell leukemia virus 
enhancer factor). 
FBXO11 (2p16.3) (F-box protein 11).  
MSH6 (2p16) (mutS homolog 6 (E. coli)).  
LOC285053 (2p16.3) (similar to ribosomal protein 
L18a). 
KCNK12 (2p22-p21) (potassium channel, subfamily K, 
member 12). 
MSH2 (2p22-p21) (mutS homolog 2, colon cancer, 
nonpolyposis type 1 (E. coli)). 
DNA/RNA 
Note: The genes for MSH2 and MSH6 which form the 
major mismatch recognition MutSalpha complex 
functional in the mismatch repair (MMR) pathway are 
located within 1 Mb of each other. MSH2 and MSH6 
may have been produced by duplication of a primordial 
mutS repair gene. 
Description 
MSH6 gene maps to NC_000002.10 and spans a region  
of 23.8 kilo bases. MSH6 has 10 exons, the sizes being 
347, 197, 170, 2545, 266, 119, 89, 155, 200 and 176 
bps. 
Transcription 
Human MSH6 gene is transcriptionally upregulated 2.5 
fold at late G1/early S phase while the amount of 
protein remains unchanged during the whole cell cycle. 
The promoter region has a high GC content, as well as 
multiple start sites. Sequence analysis of 3.9 kb of the 
5'-upstream region of the MSH6 gene revealed the 
absence of TATAA- or CAAT-boxes. Seven consensus 
binding sequences for the ubiquitous transcription 
factor Sp1 were found in the promoter region. This 
factor is implicated in positioning the RNA polymerase 
II complex at the transcriptional start sites of promoters 
lacking TATA- and CAAT-boxes. The proximal 
promoter region of MSH6 gene also contains several 
consensus binding sites of the embryonic TEA domain-
containing factor ETF. This transcription factor has 
also been reported to stimulate transcription from 
promoters lacking the TATA box. In addition, the 
trancription of MSH6 gene is downregulated by CpG 
methylation of the promoter region. 
Three common polymorphic variants (-557 T G, -448 
G A, and -159 C T) of the MSH6 promoter have been 
identified in which different Sp1 sites were inactiva ed 
by single-nucleotide polymorphisms (SNPs) resulting 
in altered promoter activity. 
 
 
Exons are represented by gray boxes (in scale) with exon numbers on the bottom. The arrows show the ATG and the stop codons 
respectively. 
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Pseudogene 
No pseudogene has been reported for the MSH6 gene. 
Protein 
Note: Eukaryotic MutSalpha is a heterodimer of the 
100-kDa MSH2 and the 160-kDa MSH6 that 
participates in the mismatch repair pathway. The 
proteins are required for single base and frameshift 
mispair specific binding, a result consistent with the 
finding that tumour-derived cell lines devoid of either 
protein have a mutator phenotype. 
Description 
The MSH6 protein maps to NP_000170 and has 1360 
amino acids. The molecular weight is 152786 Da. The
protein contains a highly conserved helix-turn-helix 
domain associated with a Walker-A motif (an adenine 
nucleotide and magnesium binding motif) with ATPase 
activity. 
The breast cancer 1 gene (BRCA1) product is part of a 
large multisubunit protein complex of tumor 
suppressors, DNA damage sensors, and signal 
transducers. This complex is called BASC, for 
'BRCA1-associated genome surveillance complex and 
the mismatch repair protein MSH6 was found to be a 
part of this complex. 
Localisation 
The subcellular localisation of MSH6 is the nucleus. 
Function 
hMSH6 gene product with hMSH2, hMSH3 gene 
products play role in strand specific repair of DNA 
replication errors. Studies show that hMSH2-hMSH6 
complex functions in the recognition step of the repair 
of base-base mismatches or single frameshifts. 
The ADP/ATP binding domain of the heterodimer and 
the associated ATPase activity function to regulate 
mismatch binding as a molecular switch. Both MSH2 
and MSH6 can simultaneously bind ATP. The MSH6 
subunit contains the high-affinity ATP binding site and 
MSH2 contains a high-affinity ADP binding site. 
Stable binding of ATP to MSH6 results in a decreased 
affinity of MSH2 for ADP, and binding to mispaired 
DNA stabilizes the binding of ATP to MSH6. Mispair 
binding encourages a dual-occupancy state with ATP 
bound to Msh6 and Msh2; following which there is a 
hydrolysis-independent sliding along DNA. Subsequent 
steps result in the excision of the mispaired region 
followed by DNA synthesis and ligation. 
Homology 
H.sapiens: MSH6 (mutS homolog 6 (E. coli)). 
C.familiaris: LOC474585 (similar to mutS homolog 6).
M.musculus: Msh6 (mutS homolog 6 (E. coli)). 
C.elegans: msh-6 (MSH (MutS Homolog) family). 
S.pombe: SPCC285.16c (hypothetical protein). 
 
S.cerevisiae: MSH6 (Mismatch repair protein). 
A.thaliana: MSH6 (MSH6). 
Mutations 
Note: The MSH6 gene plays a role in the development 
of inherited cancers, especially the colorectum and 
endometrial cancers. 
Germinal 
MSH6 germline mutations have variable penetration. 
Atypical hereditary non polyposis colorectal cancer 
(HNPCC) can result from germline mutations in 
MSH6; however, disease-causing germline mutations 
of MSH6 are rare in HNPCC and HNPCC-like 
families. Other studies have indicated that germline 
MSH6 mutations may contribute to a subset of early-
onset colorectal cancer. 
Somatic 
The involvement of somatic or epigenetic inactivation 
of hMSH6 is rare in colorectal cancer and missense 
mutations in MSH6 are often clinically innocuous or 
have a low penetrance. However, somatic mutations of 
MSH6 have been shown to confer resistance to 
alkylating agents such as temozolomide in malignant 
gliomas in vivo. This concurrently results in 
accelerated mutagenesis in resistant clones as a 
consequence of continued exposure to alkylating agents 
in the presence of defective mismatch repair. 
Therefore, when MSH6 is inactivated in gliomas, there 
is a change in status of the alkylating agents from 
induction of tumour cell death to promotion of 
neoplastic progression. 
Implicated in 
Hereditary non polyposis colorectal 
cancer 
Disease 
Mutations in the mismatch repair genes MSH2, MSH6, 
MLH1 and PMS2 results in hereditary non polyposis 
colorectal cancer (HNPCC, Lynch syndrome). 
Individuals predisposed to this syndrome have 
increased lifetime risk of developing colorectal, 
endometrial and other cancers. The resulting mismatch 
repair deficiency leads to microsatellite instability 
which is the hallmark of tumors arising within this 
syndrome, as well as a variable proportion of sporadic 
tumors. 
Clinically, HNPCC can be divided into two subgroups:  
Type I: a young onset age for hereditary colorectal 
cancer, and carcinoma of the proximal colon. 
Type II: patients are susceptible to cancers in tissue  
such as the colon, uterus, ovary, breast, stomach, small 
intestine and skin. 
Diagnosis of classical HNPCC is based on the 
Amsterdam criteria:  
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- 3 or more relatives affected by colorectal cancer, one 
a first degree relative of the other two;  
- 2 or more generation affected;  
- 1 or more colorectal cancers presenting before 50 




Turcot syndrome is a condition whereby central 
nervous system malignant tumours are associated with 
familial colorectal cancer. A homozygous mutation in 
MSH6 has been reported in a family with childhood-
onset brain tumour, lymphoma, colorectal cancer, and 
neurofibromatosis type 1 phenotype. 
Colorectal cancer 
Disease 
Mutations in four mismatch repair genes MSH2, 
MLH1, MSH6, and PMS2, have been convincingly 
linked to susceptibility of hereditary nonpolyposis 
colorectal cancer (HNPCC)/Lynch syndrome. Of the 
500 different HNPCC-associated MMR gene mutations 
known, approximately 10% are associated with 
mutations in the MSH6 gene. 
Endometrial cancer 
Disease 
Germline mutations in the MSH6 gene are often 
observed in HNPCC-like families with an increased 
frequency of endometrial cancer. Sequence analysis of 
the MSH6 coding region revealed the presence of three 
putative missense mutations in patients with atypical 
family histories that do not meet HNPCC criteria. 
MSH6 mutations may contribute to the etiology of 




Late-onset endometrioid type of ovarian cancer can be 
linked to MSH6 germline mutations. 
Lung cancer 
Disease 
Early onset lung cancer (before age 50) has been 
associated with polymorphisms in the MSH6 gene. 
Cadmium, an environmental and occupational 
carcinogen associated with lung cancer development 




Mutations in the MSH6 gene are not usually connected 
with breast cancer, even when associated with 
endometrial or colorectal cancer. 
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